» Articles » PMID: 31760445

Simultaneous Detection and Quantification of DNA and Protein Biomarkers in Spectrum of Cardiovascular Diseases in a Microfluidic Microbead Chip

Overview
Specialty Chemistry
Date 2019 Nov 25
PMID 31760445
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The rapid and simultaneous detection of DNA and protein biomarkers is necessary to detect the outbreak of a disease or to monitor a disease. For example, cardiovascular diseases are a major cause of adult mortality worldwide. We have developed a rapidly adaptable platform to assess biomarkers using a microfluidic technology. Our model mimics autoantibodies against three proteins, C-reactive protein (CRP), brain natriuretic peptide (BNP), and low-density lipoprotein (LDL). Cell-free mitochondrial DNA (cfmDNA) and DNA controls are detected via fluorescence probes. The biomarkers are covalently bound on the surface of size- (11-15 μm) and dual-color encoded microbeads and immobilized as planar layer in a microfluidic chip flow cell. Binding events of target molecules were analyzed by fluorescence measurements with a fully automatized fluorescence microscope (end-point and real-time) developed in house. The model system was optimized for buffers and immobilization strategies of the microbeads to enable the simultaneous detection of protein and DNA biomarkers. All prime target molecules (anti-CRP, anti-BNP, anti-LDL, cfmDNA) and the controls were successfully detected both in independent reactions and simultaneously. In addition, the biomarkers could also be detected in spiked human serum in a similar way as in the optimized buffer system. The detection limit specified by the manufacturer is reduced by at least a factor of five for each biomarker as a result of the antibody detection and kinetic experiments indicate that nearly 50 % of the fluorescence intensity is achieved within 7 min. For rapid data inspection, we have developed the open source software digilogger, which can be applied for data evaluation and visualization. Graphical abstract.

Citing Articles

Nucleotide detection mechanism and comparison based on low-dimensional materials: A review.

Azeem M, Shafa M, Aamir M, Zubair M, Souayeh B, Alam M Front Bioeng Biotechnol. 2023; 11:1117871.

PMID: 36937765 PMC: 10018150. DOI: 10.3389/fbioe.2023.1117871.


Biomedical Applications of Microfluidic Devices: A Review.

Gharib G, Butun I, Muganli Z, Kozalak G, Namli I, Seyedmirzaei Sarraf S Biosensors (Basel). 2022; 12(11).

PMID: 36421141 PMC: 9688231. DOI: 10.3390/bios12111023.


Microfluidic Point-of-Care (POC) Devices in Early Diagnosis: A Review of Opportunities and Challenges.

Yang S, Lv S, Zhang W, Cui Y Sensors (Basel). 2022; 22(4).

PMID: 35214519 PMC: 8875995. DOI: 10.3390/s22041620.


A multiparametric fluorescence assay for screening aptamer-protein interactions based on microbeads.

Schmidt C, Kammel A, Tanner J, Kinghorn A, Khan M, Lehmann W Sci Rep. 2022; 12(1):2961.

PMID: 35194086 PMC: 8863788. DOI: 10.1038/s41598-022-06817-0.


Microfluidics in cardiovascular disease research: state of the art and future outlook.

Ma Q, Ma H, Xu F, Wang X, Sun W Microsyst Nanoeng. 2021; 7:19.

PMID: 34567733 PMC: 8433381. DOI: 10.1038/s41378-021-00245-2.


References
1.
GALLIZIA A, de Lalla C, Nardone E, Santambrogio P, Brandazza A, Sidoli A . Production of a soluble and functional recombinant streptavidin in Escherichia coli. Protein Expr Purif. 1998; 14(2):192-6. DOI: 10.1006/prep.1998.0930. View

2.
McDonnell B, Hearty S, Leonard P, OKennedy R . Cardiac biomarkers and the case for point-of-care testing. Clin Biochem. 2009; 42(7-8):549-61. DOI: 10.1016/j.clinbiochem.2009.01.019. View

3.
Geidel S, Peransi Llopis S, Rodrigo M, de Diego-Castilla G, Sousa A, Nestler J . Integration of an Optical Ring Resonator Biosensor into a Self-Contained Microfluidic Cartridge with Active, Single-Shot Micropumps. Micromachines (Basel). 2018; 7(9). PMC: 6189757. DOI: 10.3390/mi7090153. View

4.
Wu J, Dong M, Santos S, Rigatto C, Liu Y, Lin F . Lab-on-a-Chip Platforms for Detection of Cardiovascular Disease and Cancer Biomarkers. Sensors (Basel). 2017; 17(12). PMC: 5751502. DOI: 10.3390/s17122934. View

5.
. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View